Compare TBBK & HCM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | TBBK | HCM |
|---|---|---|
| Founded | 1999 | 2000 |
| Country | United States | Hong Kong |
| Employees | N/A | 1796 |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.3B |
| IPO Year | 2005 | N/A |
| Metric | TBBK | HCM |
|---|---|---|
| Price | $52.75 | $12.70 |
| Analyst Decision | Buy | Sell |
| Analyst Count | 3 | 1 |
| Target Price | ★ $69.00 | $13.75 |
| AVG Volume (30 Days) | ★ 382.4K | 27.2K |
| Earning Date | 04-23-2026 | 03-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 14.69 | N/A |
| EPS | ★ 1.41 | N/A |
| Revenue | ★ $141,147,000.00 | N/A |
| Revenue This Year | N/A | $20.60 |
| Revenue Next Year | $8.16 | $15.62 |
| P/E Ratio | $38.07 | ★ $5.49 |
| Revenue Growth | ★ 20.85 | N/A |
| 52 Week Low | $48.86 | $12.53 |
| 52 Week High | $81.65 | $19.50 |
| Indicator | TBBK | HCM |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 28.98 |
| Support Level | $50.85 | N/A |
| Resistance Level | $55.74 | $15.75 |
| Average True Range (ATR) | 1.99 | 0.32 |
| MACD | -0.93 | -0.10 |
| Stochastic Oscillator | 5.07 | 10.38 |
The Bancorp Inc is a financial holding company. The Company's operations are classified under three segments: fintech, Credit Solutions (three sub-segments), and corporate. The fintech segment includes the deposit balances and non-interest income generated by prepaid, debit, and other card-accessed accounts, ACH processing, and other payments-related processing. It also includes loan balances and interest and non-interest income from credit products generated through payment relationships; Credit Solutions includes REBL (real estate bridge lending), comprised of apartment building rehabilitation loans, and Others; Corporate includes the Company's investment securities, corporate overhead, and expenses which have not been allocated to segments.
HUTCHMED (China) Ltd is a biopharmaceutical company engaged in the discovery, development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies world-wide and an extensive commercial infrastructure in its home market, China. The company operates in two reportable segments: Oncology/Immunology and Other Ventures.